Intas Rumored As Another Suitor For Biogen’s Biosimilars Business

Reports Of Interest From Accord Parent Company Follow Earlier Samsung Bioepis Rumor

 
• By David Wallace
  
M&A written on red and blue blocks
Biogen has seen interest from multiple parties in its biosimilars business • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Deals

More from Business